ARC Ento Tech
Wholesale Investors Only

ARC Ento Tech

ARC Ento Tech
ARC Ento Tech
|
Last Updated 10.04.2024

Recover, Re-form, Re-purpose. (For Wholesale Investors Only)

ARC Ento Tech
Min. Investment
$10,000
Objective
Growth
Structure
Company
Asset Class
Shares/​Equity
Liquidity
Illiquid
Closing Date
Subject to Capital Raising
View More Details
Min. Investment
$10,000
Objective
Growth
Structure
Company
Asset Class
Shares/​Equity
Liquidity
Illiquid
Closing Date
Subject to Capital Raising
Industry
Biotechnology, ESG/​Socially Responsible/​Impact, Mining, Resources & Energy, Other
Funding Stage
series A, B, C
Security Type
Share in a security
Target Capital
$5,000,000
Availability
Open for investment

Pre-money Valuation
$20,000,000
Raising
$5,000,000
Issue Price
Class A $2.50
Industry
Renewables

 

The ARC Process™ consists of processes that are used to recover, re-form and re-purpose all mixed unsegregated waste components.

 

From the recovery of nutrients from the organic waste components to the conversion of plastic waste into hydrogen and industrial carbon, this technology forms the foundation for real solutions to global waste challenges.

 

The technology utilises an innovative approach to waste recovery and upcycling and is protected under a patent pending.

 

Strong business model that meets the 3 pillars of sustainability – People, Planet, Profit.

 

Collaborations with 3 universities on further research that will enhance value.

 

Three pending grant applications with both the NSW and Federal Governments on a research grant for hydrogen recovery as well as commercialisation of the ARC process for recovering waste plastic.

 

Arc Ento Tech was incorporated in Australia in Feb 2020 after conducting proof of concept trials overseas. Its focus is on the use of insects to recover nutrients from organic waste and combining with a novel approach to recovering and converting all plastic waste into viable commercial products.

 

The company has established both markets and clients for the sale and supply of waste, as well as waste derived products and is ready to commercialise the first set of plants.

 

This is leading edge technology that will change the landscape of waste processing around the world. Following on from the demonstration and initial start-up plants there are already discussions to construct and operate at least seven full scale plants as early as 2024 with overseas expansion following shortly after.

 

Series 2A Capital Raising of A$5M with a pre-money valuation of A$20M.

Offering 2 million Class A shares at A$2.50 per share.

  • A$800K - Expansion of the in-house plant capacity at the Somersby facility.
  • A$4.2M - Construction of two additional commercial plants to process mixed soiled waste.

 

The content on this site is provided solely for information purposes, is not a recommendation or an offer to buy or sell a security and is not warranted to be correct, complete or accurate. This site is intended for Accredited/Sophisticated/Wholesale investors only. By continuing with an investment, you are self-accrediting that you so qualify. To the extent permitted by law, neither PrimaryMarkets, its affiliates, nor the content providers (such as the issuers of securities who appear on the site) are responsible for any investment decisions, damages or losses resulting from, or related to, the content, data and analyses or their use. The investment opportunities on this site and any statements made about them by their issuers are not vetted or verified by PrimaryMarkets. Investing in securities in private or unlisted companies and Funds is speculative and involves a high degree of risk. The investor must be prepared to withstand a total loss of their investment. We strongly encourage the investor to seek independent financial, professional or investment advice before investing in securities. The presence of an investment opportunities on this site should not be interpreted as an implied endorsement of it by PrimaryMarkets. Some content provided may constitute a summary or extract of another document. Past performance does not necessarily indicate future performance. The content on this site was current as at date of initial publication but may not be current as at the date of your viewing. For a more complete understanding of all the terms and conditions of your use of this site click here.

ARC Ento Tech Ltd is a 100% Australian owned public company. 

 

Incorporated in New South Wales, Australia in March 2020, ARC Ento Tech Ltd developed and owns the patent pending technology for the ARC Process™ and all its proprietary systems.

Ramon Atayde - Chairman & Managing Director 

Ricky Atayde - Chief Operating Officer & Executive Director

Ignacio Gimenez - Non Executive Director

Lahlit Kumar Seghal - Senior Advisor Metallurgy

Miguel Palomares - Accounting

Click here to complete the expression of interest form.

Click here to view our latest News & Events.

•    By clicking the enquire button on the card view 


  
Or 

•    By selecting “Receive Info” when viewing the listing 


  
We will respond using your preferred communication method (i.e., email or phone).

Published by PrimaryMarkets Pty Ltd

Want More Information?

Visit Website

Published by PrimaryMarkets Pty Ltd

Statutory Statement

This offer of securities is available to sophisticated investors only. This product listing was vetted by and approved by the issuer identified above before publishing. Investment Markets (Aust) Pty Ltd AFSL 527875 (IM) is not the issuer of the securities.

General Disclaimer

IMPORTANT STATEMENT ABOUT YOUR USE OF THIS SITE

Information on this site is intended for Australian users only.

This site is operated by Investment Markets (Aust) Pty Ltd. (ACN 634 057 248) (IMA, we, us and our), the holder of Australian Financial Services Licence (AFSL) no. 527875. The content is provided solely for information purposes, is not a recommendation or an offer to buy or sell a security, and is not warranted to be correct, complete or accurate. To the extent permitted by law, neither IMA, its affiliates, nor the content providers (such as the issuers of securities who appear on the site) are responsible for any investment decisions, damages or losses resulting from, or related to, the content, data and analyses or their use. The investment products on this site and any statements made about them by their issuers are not vetted, verified or researched by IMA. The presence of an investment product on this site should not be interpreted as an implied endorsement of it by IMA. Certain content provided may constitute a summary or extract of another document such as a Product Disclosure Statement. To the extent any content is general advice, it has been prepared by IMA. Any general advice has been provided without reference to your investment objectives, financial situations or needs. For more information refer to our Financial Services Guide. To obtain advice tailored to your situation, contact a financial advisor. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (or other offer document) before making any decision to invest. Past performance does not necessarily indicate an investment product’s future performance. The content is current as at date of initial publication and may not be current as at your date of viewing. For a more complete understanding of all the terms and conditions of your use of this site click here.

Subscribe to our newsletter

Elevate your investment game with our exclusive weekly newsletter, curated for astute investors like you. Dive into deep market insights and uncover a purposely broad range of unfiltered opportunities. Join a community that thrives on informed choices. Don't just follow the market—lead it.